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1. Introduction 
The distinction between antibiotic and non antibiotic medications is in fact quite arbitrary as 
drugs against bacteria can have unpredictable side effects in man and drugs developed for 
use in humans can affect microbes. It would be extremely surprising if it was otherwise, as 
eukaryotes and prokaryotes are related by evolution and share conserved molecular 
mechanisms. Many antibiotic and non antibiotic medications have closely related 
chemistries and share the same historic roots.  
For example, both antimicrobial activity and an affinity for brain tissue of the phenothiazine 
compound methylene blue were described by Paul Ehrlich in the 19th century. Early uses of 
phenothiazines included treatment of urinary tract infection and postoperative analgesia. As 
a positive effect on psychotic patients was discovered, phenothiazines became with the 
development of chlorpromazine an important tool in psychiatry (Williams, 1995). With the 
discovery of penicillin the antimicrobial activities of phenothiazines and other earlier 
compounds fell into the background, but with the emergent problem of antibiotic resistance 
in more recent years there was new interest. Phenothiazines have activity against multidrug 
resistant Staphylococcus aureus and Enterococcus faecalis, presumably through the inhibition of 
bacterial efflux pumps (Kristiansen J.E. et al., 2007).   
As a routine, antibiotic medications are tested for their effects on the eukaryotic host as these 
constitute potential side effects. While the ideal antibiotic would have no side effects at all, 
the discovery of unexpected side effects has lead to important drug developments. For 
instance, the clinical observation of a hypoglycemic effect of sulfonamide antibiotics led to 
the development of sulfonylureas for the treatment of diabetes. Likewise the observation 
that Sulfanilamide causes hens to lay eggs without shells because of alkaline diuresis led to 
the development of acetazolamide and ultimately the thiazide diuretics. The initial 
observation derived from the similarity between the sulfonamide ion and the bicarbonate 
ion. The antiviral amantadine was found to be useful in the treatment of Parkinson’s disease 
and motility agents to treat gastroparesis are derived from the observation of the 
bothersome gastrointestinal side effects of erythromycin. As described below, even Lipitor, 
the “best selling drug in the world” with $11 Billion of annual sales according to Forbes 
magazine, was developed from a compound initially discovered as an antibiotic originating 
from a fungal broth. 
On the other hand side, the efforts to look into the unintended effects on microbes of non 
antibiotic medications have been less systematic.  Non antibiotic medications can affect 
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microbes in various ways: Compounds may have direct anti microbial effects in vitro, 
similar to traditional antibiotics. However, to be clinically useful the drug level to achieve 
minimum inhibitory concentration has to be within a range that is achievable and tolerable 
in humans.  Compounds can exert an antimicrobial effect by inhibition of bacterial pumps. 
A well known example is the potentiation of antibiotic treatment against Helicobacter pylori 
through omeprazole. Many psychotropic medications including the phenothiazines fall into 
this category. Aspirin appears to modulate the expression of genes that are important for 
Staphylococcal virulence and the statins appear to have immune modulatory effects. Both 
medications are discussed in more detail below. 
This chapter deals with the anti microbial effects of medications that are not traditionally 
regarded as antibiotics with regards to dialysis. 
2. A combination of unfortunate events: infection in dialysis 
The current epidemic of obesity and, as a complication, diabetic nephropathy associated to 
type 2 diabetes mellitus has fueled the spectacular growth of hemodialysis into an industry 
that is dominated by a handful of large companies. Infection is a leading cause of morbidity 
and mortality in dialysis patients and the annual mortality rate caused by sepsis is several 
hundred folds higher in patients with end stage renal disease than in the general population 
(Laupland et al., 2004). The incidence of bacteremia has increased in hemodialysis patients 
over the years, mainly because of increased rates of serious Staphylococcus aureus infection in 
this population (Foley at al., 2004). S. aureus has its name from a gold coloured caroten 
virulence factor called staphyloxanthin which allows the bacteria to survive oxidative bursts 
of neutrophils (Liu G.Y. & Nizet V., 2009).  S.aureus produces a battery of surface proteins, 
enzymes and toxins which enable the bacteria to both persist in intracellular locations and in 
biofilms for long periods of time, and to rapidly disseminate in the host in an opportunistic 
fashion which makes it one of the most dangerous and pathogenic bacteria in humans. 
The use of dialysis catheters is a major risk factor for developing S.aureus infection because 
of disruption of the normal skin barrier, thus forming a gateway for bacterial entry into the 
blood stream (Vandecasteele S.J. et al., 2009). Despite Kidney Disease Outcomes Quality 
Initiative clinical practice guidelines recommending the use of auto logos arterio-venous 
fistulae as dialysis access and other efforts, the overall prevalence of hemodialysis catheter 
use has been increasing, approaching 30% in the United States (Rayner et al., 2004). Humans 
are the main natural reservoir for S.aureus which can colonize skin, gastrointestinal and 
urogenital tracts. The most frequent site of colonization is the anterior nose and longitudinal 
studies have shown that there are three types of S.aureus nasal carriage in healthy adults: 
fifty percent are persistent non carriers, thirty percent are intermittent carriers and twenty 
percent are persistent carriers (VandenBergh et al., 1999). Hands are the main vector of 
transmission and in the majority of cases the same strain that is found in the bloodstream is 
also found on the hands and in the nose (von Eiff C. et al., 2001). It follows that rigorous 
hand washing is extremely important to prevent infection in the dialysis units as it is 
elsewhere in the medical setting. The majority of S.aureus infections has its source in the 
endogenous reservoir in the nose of the same person and can thus be considered an 
“autoinfection” (Boelart et al., 1995 as quoted in Vandecasteele et al., 2009). Consistent with 
this view is that in prospective studies the interval between catheter placement and 
staphylococcemia can be very short, with 23% of episodes occurring less than one week after 
catheter insertion (Little M.A. et al., 2001). S.aureus bacteremia is associated frequently with 
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metastatic infection such as endocarditis, osteoarticular infection, septic pulmonary 
embolism and epidural abscess and carries a mortality that is higher than with other 
pathogens. While the original observation by Fleming that led to the discovery of penicillin 
involved the accidental overgrowth of an S.aureus culture with fungus, staphylococcal 
resistance to penicillin has since become very frequent both in community and hospital 
acquired infections. A recent study in the US found that methicillin resistant S.aureus 
accounted for 65% of isolates from the nose in hospitalized dialysis patients (Johnson L.B. et 
al., 2009). As with methicillin sensive S.aureus, colonization seems to precede clinical 
infection. A scheme of three times a week nasal mupirocin ointment can decrease nasal 
carriage but is cumbersome, the rate of recurrence is high and rapid development of 
resistance has been observed (Vandecasteele et al., 2009). 
3. Salicylic acid 
Salicylic acid, the active ingredient of willow bark, is one of the oldest medicines still in use, 
in the buffered form of aspirin. The beneficial effect on fever, pain and inflammation were 
already described by Hippocrates. Fallen out of favour because of other non steroidal anti 
inflammatory drugs with more favorable side effects profiles aspirin has made a spectacular 
come back fifty years ago as the antiplatelet effects of aspirin were discovered. Since then 
aspirin has found widespread therapeutic use in the treatment of cardiovascular disease. 
Chronic treatment with Aspirin may prevent colorectal cancer, presumably by inhibition of 
cyclooxygenase 2 (COX-2) which is expressed in large amounts in adenocarcinoma (Ruder 
E.H. et al., 2011). Salicylic acid is ubiquitous in plants as a phytohormone. It is part of the 
innate immune system of plants, involved in local resistance to pathogens and in systemic 
acquired resistance (SAR), where a pathogenic attack one part of a plant induces resistance 
in other parts. Depending on the amount of fruit and vegetables in the diet humans have 
detectable serum levels of salicylic acid. It has been hypothesized that diet derived salicylic 
acid could in part account for the observed link between diet and colorectal cancer (Paterson 
J.R.& Lawrence J.R., 2001) and this might possibly apply to the relation between diet and 
cardiovascular disease as well. Salicylic acid is used as a food preservative and an antiseptic 
in toothpaste. Aspirin is thus not only one of the oldest but also one of the most versatile 
and successful drugs known.  
3.1 Laboratory evidence for an anti staphylococcal effect of salicylic acid 
Early studies in the rabbit endocarditis model showed that platelets provide a nidus for 
bacteria and that aspirin can decrease vegetation size (Pujadas et al., 1988). The observation 
was made that aspirin can reduce not only the weight of vegetations in a rabbit model of 
S.aureus endocarditis but also bacterial density although neither aspirin nor salicylic acid 
have known antibacterial effects at the low concentrations employed (Nicolau D.P. et al., 
1993). This benefit was seen if aspirin was given together with antibiotics but also if aspirin 
was provided prior to the infectious challenge with which endocarditis was induced 
(Nicolau D.P. et al., 1995). Even more puzzling in this study was that vegetation weight and 
bacterial density were higher if higher doses of aspirin were administered while the 
optimum beneficial effect was seen at a lower dose, suggesting that serum levels may be 
very important. Subsequently this observation has been called the “Goldilocks effect” in 
which too little and too much aspirin may cause paradoxically diminished effects on 
outcome parameters in the infectious endocarditis model (Eisen et al., 2008). The beneficial 
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effects of aspirin in the rabbit model of endocarditis have been recapitulated with salicylic 
acid, its major biometabolite (Kupferwasser et al., 1999). As salicylic acid has no anti-platelet 
properties, this indicates that platelet independent mechanisms are likely to have a more 
significant role in the action of aspirin on S.aureus endocarditis that the platelet dependant 
effects. Further experimental work in vivo in animal models of infectious S.aureus 
endocarditis showed that aspirin reduced a multitude of measurable parameters of the 
severity of the infection and metastasis such as vegetation weight and the bacterial density 
in vegetations and the number of renal emboli and these effects were dose dependant, more 
pronounced at lower rather than higher doses (Kupferwasser et al., 1999). In vitro studies 
showed that salicylic acid inhibits the expression of two key virulence genes in S. aureus that 
are involved in endovascular pathogenesis: alpha-toxin [hla] and fibronectin-binding 
adhesion [fnbA], through activation of genetic pathways involving the major stress response 
operon, sigma factor B (Kupferwasser et al., 2003). These aspirin mediated effects on sigma 
factor B were observed at serum concentrations that are achieved by usual clinical dosages 
of aspirin in humans (Kupferwasser et al., 2003). On the other hand side, it has been shown 
that the presence of salicylic acid decreases expression of capsular polysaccharides. It has 
been hypothesized that the loss of these capsular virulence factors could lead to an increased 
capacity of S.aureus to invade epithelial cells and that chronic treatment with aspirin could 
potentially lead to more persistent or recurrent infection (Alvarez C.P. et al., 2010). 
In conclusion a significant body of in vitro and in vivo evidence indicates that aspirin may 
have the potential to be useful in the treatment of S.aureus infection by down modulating 
key regulator and structural genes resulting in the abrogation of virulent phenotypes but it 
has to be noted that important questions remain. 
3.2 Clinical evidence for a beneficial effect of aspirin in S.aureus endocarditis 
The earliest clinical observations of a potential salutatory role of aspirin come from the 
study of bacterial endocarditis. In a small retrospective study a decreased rate of embolic 
events was found in patients with native valve endocarditis who were on long term aspirin 
treatment (11% versus 47%), although the number of patients treated with aspirin was too 
small to be conclusive (Schunemann S. et al., 1997). A small preliminary prospective 
observational study conducted in 9 patients found adjunctive treatment of established 
endocarditis with aspirin beneficial (Taha et al., 1992). 
Subsequently, a Canadian prospective multicenter study in 115 patients with endocarditis 
showed no benefit of the adjunctive treatment with a 325mg dose of aspirin (Chan et al., 
2003). Despite its prospective design this study was criticized as patients on chronic aspirin 
treatment were excluded from this study although the greatest benefit might be expected in 
this population. Moreover, Aspirin was added only after an average of 35 days after onset of 
symptoms. Only 14 patients (25%) in the Aspirin treatment group had Staphylococcus aureus 
endocarditis while the majority had streptococcal endocarditis. As the putative mechanism 
of action of aspirin involves the inhibition of S.aureus virulence factors, the benefit of aspirin 
is likely greatest if it is used before infection occurs. The benefit of aspirin is also very likely 
to be limited to S.aureus as the mechanism seems to be specific to this pathogen. The same 
authors presented a post hoc analysis of their data in 2008, comparing 84 patients who had 
been excluded from their previous study because of long term aspirin treatment with 54 
patients in the placebo arm and again found no significant clinical differences in the 
outcome between both groups (Chan et al., 2008). Only 29% of patients, 16 and 24 patients 
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respectively, in both arms had S.aureus endocarditis and thus the same concern that the 
study was underpowered to detect a difference was voiced for this study as well (Eisen D.P. 
& Bayer A.S., 2008).  
A retrospective single center cohort study of 600 patients with infectious endocarditis, who 
were treated over a 18 year period at the Mayo Clinic, found that the odds of suffering 
symptomatic embolic events was decreased by 64% in patients who were treated with 
antiplatelet agents for at least 6 months prior to the diagnosis: Aspirin was the antiplatelet 
agent in 98% of cases and an 81mg daily dose was used in the majority of patients 
(Anavekar et al., 2007). 
Eisen et al. used the International Collaboration on Endocarditis –Prospective Cohort Study 
(ICE-PCS) database to assess the influence of aspirin usage at the time of diagnosis on the 
outcome of definitive S.aureus endocarditis. A cohort of 670 patients had both information 
on prior aspirin use and S.aureus endocarditis. Aspirin use at the time of diagnosis in 132 
patients was a predictor for a decreased risk of acute valve surgery, independent of 
methicillin resistance status. A statistically significant decrease in embolic events in aspirin 
users was found in a univariate analysis that became a trend in multivariate analysis. A 
comparison of groups with and without aspirin use among patients with Streptococcal 
endocarditis was made and no association of aspirin with improved outcomes was found 
(Eisen et al., 2009).  
Thus the data on aspirin use in S.aureus endocarditis suggests that aspirin likely does alter 
the course of illness. The non dependence of the effect on methicillin resistance status and 
the absence of an observed effect of aspirin on other pathogens are consistent with the 
proposed specific mechanism of aspirin on staphylococcal virulence factors. It is also 
noteworthy that Staphylococcal endocarditis is rather difficult to study in adequate numbers 
as the population incidence is fortunately low.  
3.3 Aspirin and S.aureus nasal carriage 
Karabay et al. investigated the prevalence of S.aureus nasal carriage in an outpatient cardiology 
clinic. Of a total of 346 patients 199 were chronic aspirin user while 147 patients were not. The 
prevalence of S.aureus nasal carriage was 5% on patient treated chronically with aspirin versus 
16% in those that did not take aspirin. Only aspirin was found to be associated with a 
decreased rate of nasal carriage in a multivariate analysis (Karabay et al., 2006). These findings 
are of obvious significance to hemodialysis patients as nasal colonization is considered the 
initiating event that leads to catheter associated staphylococcal bacteremia. If confirmed, 
aspirin could decrease nasal carriage at a fraction of the cost and effort of mupirocin ointment. 
Given the fact that aspirin is a very old drug the findings of Karabay et al. have another 
potential significance: If a clinical effect of aspirin on S.aureus can still be detected after decades 
of over-the-counter use it would be unlikely that S.aureus would develop resistance to this 
effect in the future. It is clear that the important findings of Karabay et al. merit further 
investigation both in hemodialysis and in the general population. 
3.4 A potential beneficial effect of aspirin in hemodialysis patients 
Patient undergoing hemodialysis treatments suffer staphylococcal infections with increased 
frequency because of a high prevalence of tunneled or non tunneled dialysis catheters. The 
hemodialysis setting is thus well suited to study the potential beneficial clinical anti 
staphylococcal effects of aspirin.  
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We conducted a single center retrospective study in 872 patients with tunneled catheters who 
dialyzed over a ten year time period from 1995 to 2005.  During this time period our patients 
had 1853 tunneled dialysis catheters placed and accumulated more than 476 patient-catheter-
years and had 4722 blood cultures performed. Temporary dialysis catheters were excluded 
because of the high variability in the circumstances of placement of temporay catheters and 
also greater difficulty in tracking them retrospectively. The overall incidence of bacteremia 
was 7.2 episodes per 100 patient-catheter-months and the incidence of S.aureus bacteremia was 
2.1 episodes per 100 patient-catheter-months. The incidence of S.aureus endocarditis was 0.16 
episodes per 100 patient-catheter-months. These numbers are within the range reported in the 
literature. Blood cultures were obtained at the discretion of the treating physician if infection 
was suspected. Tunneled catheters that were a suspected source of infection were usually 
removed and negative cultures were required before insertion of a new tunneled catheter. All 
tunneled catheters were placed and removed by the same interventional radiology service. 
Suspected infection was the principal reason for tunneled catheter removal (19%), followed by 
poor catheter blood flow (14%) and presence of a mature permanent vascular access (14%). 
Infection rates were compared by Poisson regression analysis. In this study catheter associated 
bacteremia was defined as one or more positive blood cultures in a patient with a tunneled 
catheter. In retrospect it was impossible to exclude other sources of infection and 
contamination and for this reason all positive blood culture results that were obtained in the 
presence of a tunneled catheter were included without discrimination. Blood cultures that 
were obtained after a tunneled catheter was removed were excluded per definition. Our 
institution is a tertiary care medical center that offered hemodialysis in two outpatient units, 
serving a population of about 400,000 people. Because of location in a rural area, limited 
availability of hemodialysis and other geographical factors limiting access to other institutions 
the long term follow up of patients was excellent. A proprietary medical record system 
integrated electronic inpatient and outpatient records with procedure notes and laboratory, 
radiological and microbiological test result and was ideally suited for a large retrospective 
study. As a result the fate of only 8 catheters (<0.5%) was unaccounted for.  
The number of episodes and rates of catheter associated bacteria is shown in Table 1 which 
includes repeated episodes and polymicrobial infections with more than one bacterial 
isolate. As expected, Gram positive bacteria accounted for the majority of bacteremic 
episodes. When all bacteremic episodes were considered together, there was no difference 
between patients treated with aspirin or not. In fact, the only pathogen with a lower rate of 
catheter-associated bacteremia in patients treated with aspirin was S.aureus which caused 
only half as many episodes in the aspirin group compared to patients not treated with 
aspirin (0.17 versus 0.34 events/patient-catheter-years, p=0.003). In addition to blood 
cultures 369 catheter tip cultures were performed in the same time interval, albeit in a less 
systematic fashion. Of these 53 catheter tip cultures grew S.aureus. In such a case treatment 
is usually recommended because S.aureus bacteremia is considered more likely than 
contamination (Peacock et al., 1998). If these tip cultures were added to bona fide blood 
cultures in the analysis, the difference was statistically more significant: 83 instances (0.36 
events per patient-catheter-year) of S.aureus in the non aspirin treated group versus 45 (0.18 
event per patient-catheter-year) in the aspirin treated group (p=0.001).  
Moreover, if we excluded repeated events in the same patient from our data and considered 
only first episodes of S.aureus bacteremia, the difference looked between the two groups 
looked even more impressive: 28 first episodes of S.aureus bacteremia in patients treated 
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with aspirin (0.23 events per patient-catheter year) versus more than double, 64 first 
episodes of S.aureus bacteremia (0.57 events per patient catheter year) in patient not treated 
with aspirin (p<0.001). 
We explored the association between aspirin dose and rates of catheter associated S.aureus 
and MRSA bacteremia in table 2. There was a dose effect as only a 325mg dose of Aspirin, 
but not an 81mg dose (common formulations in the United States), was associated with a 
decreased rate of Staphylococcus aureus infection compared to patients not treated with 
aspirin. Importantly there was a significantly lower rates of Methicillin resistant 
Staphylococcus aureus bacteremia (MRSA) in patients treated with 325mg of aspirin a day.  
  
 
No Aspirin Aspirin P 
 
978 Catheters/227.4 
Patient-Catheter-Years
875 Catheters/ 
249.3 Patient-
Catheter-Years 
 
 
No. 
Rate 
(/patient-
catheter-y) 
No.
Rate 
(/patient-
catheter-y) 
 
All positive 232 1.02 207 0.83 0.30 
Gram-positive 
Coagulase-negative Staphylococcus 96 0.42 93 0.37 0.85 
S aureus 77 0.34 43 0.17 0.003* 
MRSA 19 0.08 11 0.04 0.16 
Enterococcus species 21 0.09 30 0.12 0.18 
Corynebacterium species 7 0.03 6 0.02 0.82 
Streptococcus species 4 0.02 7 0.03 0.34 
Bacillus species 4 0.02 4 0.02 0.97 
Gram-negative 
Enterobacter species 20 0.09 21 0.09 0.81 
Pseudomonas species 11 0.05 13 0.05 0.64 
Serratia species 12 0.05 9 0.04 0.55 
Klebsiella species 9 0.04 10 0.04 0.77 
Escherichia coli 7 0.03 4 0.02 0.39 
Acinetobacter species 4 0.02 4 0.02 0.97 
Bacteroides species 3 0.01 3 0.01 0.78 
Note: Multiple bacterial isolates and repeated episodes were included in this table. Fungal isolates and 
bacterial species found fewer than 5 times during the 10-year study period were omitted. 
*Significant difference by Poisson regression. 
Table 1. Number of Episodes and Rates of Catheter-Associated Bacteremia in a 10-Year 
Period from 1995 to 2005 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
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Table 2. Association between Aspirin Dose and Rates of Catether-Associated S aureus and 
MRSA Bacteremia 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
We used Cox proportional hazard analysis to study risk factors for developing a first episode 
of S.aureus bacteremia. Table 3 shows the patient characteristics and distribution of covariates 
that were used for this analysis. Patient treated with aspirin were on average 10 years older 
and had a higher prevalence of coronary artery disease, peripheral vascular disease, history of 
stroke, hypertension and diabetes mellitus than patients not treated with aspirin.  
Table 4 shows the result of the Cox proportional hazard analysis. Aspirin decreased the 
odds of developing a first episode of S.aureus bacteremia by 54% (with a confidence interval 
of 72% to 24%, p=0.002). No other cardiovascular medication and neither clopidogrel nor 
Warfarin had a similar effect.  Also, no beneficial effect of statins on the odds of S.aureus 
bacteremia was observed in this study. On the opposite side, the presence of diabetes 
mellitus increased the risk of developing a first episode of catheter associated S.aureus 
bacteremia, as was previous recognized (Breen et al. 1995). COPD decreased the odds of a 
first episode S.aureus bacteremia in this study. A potential explanation for this observation 
could be more frequent antibiotic use in this condition which might reduce nasal carriage. A 
greater incidence of S.aureus bacteremia was reported in patients with cardiovascular 
disease (K/DOQI, 2005) but the opposite, lower numbers of S.aureus bacteremia was 
observed in this sicker patient population which may be taken as a sign of the potential 
clinical importance of the anti staphylococcal effects of aspirin. Similar results were obtained 
when multiple logistic regression analysis was used instead of Cox analysis. 
Data on metastatic infection (endocarditis, osteomyelitis, septic arthritis) was analyzed as 
well. There were significantly less events in patients treated with aspirin compared with 
events in patients not treated with aspirin (3 versus 11 events, p=0.04). 
A Kaplan-Meier plot of cumulative catheter failure associated with S.aureus bacteremia is 
shown in Figure 1. Grouping by aspirin treatment resulted in two divergent graphs with 
catheter failure caused by S.aureus infection significantly more frequent in the non aspirin 
group (p<0.001). The two graphs diverge very early which is consistent with the clinical 
observation that almost a quarter of S.aureus infection occur very early within a week after 
catheter insertion (Little M.A. et al., 2001). Figure 1 also illustrates another measure of the 
beneficial anti staphylococcal effect of aspirin: delayed onset of infection. 
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  No Aspirin (454 patients) Aspirin (418 patients) P 
Age (y) 59 ± 19* 68 ± 13* <0.0001 
Time on dialysis (d) 362 ± 810 346 ± 542 0.73 
Catheter no. 1.8 ± 1.8 1.9 ± 1.7 0.70 
Female sex 194 (42) 186 (44) 0.54 
Tobacco use 205 (45)* 225 (54)* 0.01 
Diabetes mellitus 170 (38)* 236 (56)* <0.0001 
Hypertension 333 (74)* 364 (87)* <0.0001 
COPD 92 (20)* 117 (28)* 0.009 
Coronary artery disease 159 (35)* 309 (79)* <0.0001 
Peripheral vascular disease 113 (25)* 200 (48)* <0.0001 
Stroke 66 (15)* 99 (24)* 0.007 
Arthritis 141 (31)* 164 (39)* 0.01 
Cancer 102 (23) 80 (19) 0.24 
Previous transplant 50 (11)* 14 (3)* <0.0001 
Clopidogrel 12 (3)* 40 (10)* <0.0001 
Warfarin 61 (14) 60 (14) 0.77 
Statin 69 (15)* 172 (41)* <0.0001 
B-Blocker 248 (55)* 315 (75)* <0.0001 
ACE inhibitor/ARB 136 (30)* 187 (45)* <0.0001 
Calcium channel blocker 216 (48) 216 (52) 0.28 
Aspirin 0 418 <0.0001 
Note: Values expressed as mean ± SD or number (percent). 
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. 
*Statistically significant difference between aspirin-treated and non–aspirin-treated groups by means of 
Fisher exact test or unpaired Student t-test, as appropriate.  
Table 3. Patient Characteristic and Distribution of Covariates for the Cox Proportional 
Hazard Analysis 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With Tunneled 
Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
A second study that addressed the anti staphylococcal effects of aspirin in hemodialysis 
patients was published in abstract form (Sedlacek et al., 2008). We performed a historical 
cohort study of the United States Renal Data System (USRDS) Dialysis Morbidity and 
Mortality Study (DMMS) Wave II data, linking medication data to mortality data from the 
core files. The updated USRDS Wave II data comprise 4024 patients, 16% of which were 
treated with Aspirin at study start date and 2776 of whom died. 54 of 2262 deaths (2.39%) in 
patients not treated with aspirin were attributed to septicemia due to vascular access either 
as primary or secondary cause, while there were only 4 of 510 deaths (0.78%) in patients 
treated with aspirin that were attributed to this cause (p<0.02, 2-tailed Fisher’s Exact Test). 
Although anti platelet agents and other cardiovascular medications are underused in 
dialysis patients, we still find a strong negative association between aspirin treatment and 
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death from septicemia due to vascular access in USRDS data. These results provide a 
confirmation of a clinical anti-staphylococcal effect of aspirin in hemodialysis patient that is 
independent from the data pool used in our first study. 
 
Relative Risk (95% CI) P 
Age (y) 1.0 (1.0-1.0) 0.99 
Time on dialysis (d) 1.0 (1.0-1.001) 0.88 
Catheter no. 0.95 (0.83-1.09) 0.45 
Female sex 1.19 (0.76-1.86) 0.45 
Tobacco use 0.78 (0.49-1.24) 0.30 
Diabetes mellitus 1.65 (1.02-2.67) 0.04*
Hypertension 1.36 (0.74-2.51) 0.33 
COPD 0.49 (0.24-0.97) 0.04*
Coronary artery disease 0.80 (0.48-1.34) 0.40 
Peripheral vascular disease 1.01 (0.62-1.65) 0.97 
Stroke 1.11 (0.63-1.96) 0.72 
Arthritis 1.22 (0.78-1.92) 0.39 
Cancer 1.04 (0.59-1.83) 0.89 
Previous transplant 1.19 (0.55-2.55) 0.66 
Clopidogrel 1.06 (0.40-2.83) 0.91 
Warfarin 1.79 (1.03-3.10) 0.04*
Statin 1.08 (0.63-1.85) 0.79 
B-Blocker 1.13 (0.70-1.83) 0.62 
ACE inhibitor/ARB 0.79 (0.50-1.25) 0.31 
Calcium channel blocker 0.73 (0.46-1.15) 0.17 
Aspirin 0.46 (0.28-0.76) 0.002*
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker. 
*Statistical significance in Cox proportional hazard model.  
Table 4. Risk of First S aureus Bacteremia Episode in 872 Dialysis Patients with a Tunneled 
Catheter by using Cox Proportional Hazard Analysis 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
3.3 Concerns about aspirin use in hemodialysis patients 
The abuse of non steroidal inflammatory drugs is a well described risk factor for upper 
gastrointestinal bleeding. The concern has been raised that the use of aspirin in dialysis 
patients could be harmful by causing bleeding (Chan et al., 2003 and 2008). As noted in a 
recent metanalysis the available data is conflicting for a variety of reasons such as selection 
bias, insufficient length of follow up and concomitant treatment with proton pump 
inhibitors (Hiremath et al., 2009). In the study of Chan et al a trend towards a higher 
incidence of bleeding was observed which did not reach statistical significance as both the 
initial study as well as the subsequent post hoc analysis was underpowered to either   
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patients at risk: 
ASA              417   142    66    35    25      16      9      6      5 
no ASA         452   118    61    37    22      11      6      3      2   
Fig. 1. Cumulative plot of tunneled catheter failure associated with S aureus bacteremia. The 
failure plot was obtained using the Kaplan-Meier method. Tics represent censoring of 
catheter removal unrelated to S aureus bacteremia. Log-rank test was used to calculate P. 
Reprinted from Sedlacek et al.: “Aspirin Treatment Is Associated With a Significantly 
Decreased Risk of Staphylococcus aureus bacteremia in Hemodialysis Patients With 
Tunneled Catheters”, Am J Kidney Dis Vol49, pp401-408 with permission from Elsevier 
support or refute this hypothesis. In our own study no increased risk of bleeding was 
observed (unpublished data, Sedlacek et al., 2008). A study on aspirin use in 28320 patients 
from the Dialysis Outcomes and Practice Patterns Study I and II found neither a decreased 
cardiovascular risk nor an increase in the gastrointestinal bleeding with the use of aspirin 
(Ethier J et al., 2007). (Of note, no data on infectious complications was included in this 
manuscript which why it was not discussed in the above sections.) 
While there is no unequivocal proof that aspirin increases the risk of upper gastrointestinal 
bleeding in dialysis patients, it must not be forgotten that upper gastrointestinal bleeding is 
a well documented part of the uremic syndrome and that anticoagulation is routinely used 
during the hemodialysis procedure. It would thus seem reasonable to adopt a similar 
approach to high risk dialysis patients as has been recommended in high risk cardiac 
patients who would benefit from aspirin. Patients can be screened and treated for H.pylorii 
and proton pump inhibitors may be considered. Lastly it has to be noted that upper 
gastrointestinal bleeding is more amenable to treatment and represents a lesser risk to a 
high risk dialysis patient than for example cardiac stent occlusion. 
4. Statins 
Statins are cholesterol reducing medications that similarly to aspirin have become a 
cornerstone in the prevention and treatment of cardiovascular disease. The antimicrobial 
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effects of statins have been known for a long time. In fact, statins were discovered by 
searching for compounds that would inhibit HMG-CoA reductase in microbes that require 
sterols or other isoprenoids, which are part of bacterial cytoskeleton, for growth. The first 
statins were described as antibiotics secreted by Penicillium species. The first statin 
compound, mevastatin, is derived from a culture of Pythium ultimum and Penicillium 
citrinum and under the name compactin the same compound was isolated from a culture of 
Penicillium brevicompactum (Endo et al., 1976). A mevastatin analog currently in use, 
lovastatin, was isolated from a culture of Aspergillus terreus. (Endo A., 1992). The 
antimicrobial effects of statins were rediscovered at a later time and it was noted that the 
minimum inhibitory concentration of simvastatin for S.aureus was much higher than the 
serum levels that can be achieved during routine treatment at recommended doses (Jerwood 
S. & Cohen J., 2008). Direct antimicrobial effects with potential clinical relevance have been 
postulated for HIV, CMV, HCV, Salmonella and yeast (Gupta et al., 2007) but are perhaps 
less relevant for dialysis catheter associated infection. Newer laboratory evidence shows that 
the interferon response to viral infection of the innate immune immune system is coupled to 
the mevalonate-isoprenoid arm of the sterol pathway. These findings may explain the 
observation that the CMV and HCV viruses are sensitive to statin administration and that 
treatment with interferon decreases plasma cholesterol levels similar to treatment with 
statins (Blanc M et al., 2011). 
Several observational studies in patients with severe bacterial infections have reported 
improved survival in patients treated with statins (Bjoerkheim-Bergman et al., 2010). These 
beneficial effects appear to be greater than what might be expected with lipid lowering 
alone and are attributed to pleiotropic effects of statins. Such effects involve improving 
endothelial function, decreasing oxidative stress and inflammation and inhibiting the 
thrombogenic response (Liao J.K. & Laufs U., 2005).  
The hypothesis that treatment with statins could have an influence on the rate of septic 
events in dialysis patients was investigated by Gupta et al in 2007. The authors used data 
from a prospective study to investigate choices and outcomes of dialysis care, which 
enrolled 1041 patients from 1995 to 1998, the majority of which dialyzed in units associated 
with Dialysis Clinic Inc in Nashville TN. These patient data were linked to United States 
Renal Data System administrative data which included hospitalizations and data from other 
treatment settings, including outpatient and skilled nursing facilities. Primary outcome were 
sepsis events but “only episodes in which the primary event was sepsis were included (…) 
to avoid including cases in which infection was acquired as a secondary phenomenon” 
(Correction by the same authors in JAMA Vol 299 P 765). The correction to their method 
section published later by the authors raises the possibility that their data analysis could 
come to a different conclusion if all episodes of sepsis were considered, not only the events 
that were considered”primary”. The authors found that 143 patients (14%) received statin 
treatment compared with 898 patients (86%) who were not. Among all 1041 patients there 
were a total of 303 events of primary sepsis during a mean follow up of 3.4 years. The crude 
incidence rate of sepsis events was 63% lower in patients treated with statins compared with 
the control group (41 events per 1000 patient-years compared with 110 events per 1000 
patient years) The authors found that the odds ratio for a primary septic event in statin users 
was 0.38 (95% CI 0.21-0.67) with adjustments for demographics, dialysis modality, 
comorbidities and laboratory values. In a propensity-matched subcohort analysis statin use 
was even more protective with an odds ratio of 0.24 (CI 0.11-0.49) (Gupta et al., 2007). In 
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contrast to the results of this study no difference in the rate of death from fatal infection with 
the use of atorvastatin was found in the 4D study (Wanner et al., 2005).  
An interesting question that is raised by the study by Gupta et al. is whether the observed 
benefit could be due to concomitant treatment with aspirin (Gupta et al., 2007). Both statins 
and aspirin are used for the treatment of coronary artery disease and a head to head 
comparison would be instructive. Our aspirin study did not find a beneficial effect of statins 
on the risk of septic events (Sedlacek et al., 2007) and the study by Gupta et al. did not 
control for aspirin use.  
It has to be noted that the relation between lipid parameters and mortality in dialysis 
patients is complex, confounded by the fact that elevated serum cholesterol levels are 
paradoxically protective in this population, probably because they are a marker for the 
absence of malnutrition and inflammation. In practical terms it is advised to use low doses 
of statins to reduce side effects and to avoid the concomittant administration of other drugs 
metabolized by the cytochrome P-450 system such as cyclosporine, azole antifungals and 
fibrates (Olyaei et al., 2011). 
5. Effects of other drugs used on dialysis 
Several other drugs that are frequently used on dialysis have known interactions with 
microbes. Heparin is used frequently to block dialysis catheters when not in use to preserve 
their patency. Unfortunately, heparin has been found to promote growth of bacterial biofilm 
in dialysis catheters (Shanks et al., 2005). Citrate has been used as an alternative to heparin 
to block catheters and was found to have inhibitory effects on biofilms at elevated 
concentration. Reminiscent of the “Goldilocks effect” observed with aspirin, citrate 
stimulates biofilm formation at sub inhibitory concentrations, an effect which might have 
clinical relevance at catheter tips (Shanks et al., 2006). EDTA also has an inhibitory effect on 
biofilm. The mechanism for both EDTA and citrate is thought to be through chelation  
of divalent ions essential to the extracellular matrix structure of biofilm (Percival et al., 
2005).  
Diltiazem, Amlodipine and the angiotension converting enzyme inhibitor Zofenopril have 
modest in vitro antimicrobial activity against S.aureus. Most of these effects are 
bacteriostatic and occur at higher drug concentrations in vitro than the therapeutic 
concentrations that are usually achieved during therapy in vivo. It has to be noted however, 
that drug concentration can vary considerably throughout different organs and body 
compartments. In the case of Amiloride it has been determined that urine concentrations 
achieved in patients are not sufficient to replicate the antibacterial effects that are observed 
in vivo (Cederlund et al., 1993). The relevance of these observations probably concerns more 
microbial purity testing of drugs during the fabrication process rather than clinical effects.  
Emla cream, a mixture of lidocaine, prilocaine and preservatives, which is used for topical 
anesthesia at the site of dialysis fistula puncture, has no effect on microbial growth 
(Kruszewska et al., 2010). Other drugs relevant to ESRD that have been tested and were 
found to be devoid of antimicrobial effects are the loop diuretics furosemide and 
bumetanide. 
The antihistaminic drug diphenhydramine has been reported to be synergistic with the 
penicillins (Kristiansen, 1992) and amiloride reportedly enhances uptake of tobramycin in 
pseudomonas aeruginosa (Cederlund et al., 1993). 
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6. Last but not least: Honey 
Honey has been used for the treatment of wounds since ancient times and its medicinal use 
is sanctioned by the Bible, Torah and Koran (Namias N., 2003). Johnson et al. conducted a 
prospective trial of topical honey versus topical Mupirocin ointment for the prevention of 
dialysis catheter associated infection. In a two year study period the authors enrolled 101 
patients with tunneled dialysis catheters in their hospital based dialysis unit. Honey was 
applied three times a week to the dialysis catheter exit site in 51 patients while mupirocin 
ointment was used in 50 patients. No exit site infections were observed in either group and 
no difference in the rate of catheter associated bacteremia could be demonstrated. The cost 
of the Australian grown medicinal honey that the authors used was equivalent to 
mupirocin. As the authors noted, it is interesting that at the time of the study about 2% of 
staphylococcal isolates in their hospital were resistant to mupirocin while no bacterial 
resistance to honey has yet been reported despite millennia of being around (Johnson D.W. 
et al., 2005). 
7. Conclusion 
In summary, a couple of observational studies have shown that both aspirin and statins 
might have significant salutatory effects on infectious complications in hemodialysis 
patients. Of note, aspirin does not have growth inhibitory or bactericidal activity at 
pharmacologically relevant concentrations and thus may be less likely to promote bacterial 
resistance as traditional antimicrobials do (Eisen et al., 2009). The same might apply for 
statins as well (Jerwood & Cohen, 2008). However, retrospective and observational studies 
are prone to multiple sources of bias that are unquantifiable and of indeterminate direction. 
Thus, randomized prospective trials are needed to further investigate this exciting new 
approach to the prevention of infectious complications in dialysis patients.  
8. References 
Alvarez, L.P.; Barbagelata, M.S.; Gordiola M.; Cheung A.L.; Sordelli D.O.& Buzzola F.R. 
(2010). Salicylic acid diminishes staphylococcus aureus capsular polysaccharide 
Type 5 expression.  Infection Immunology, Vol.78, (2010), pp. 1339-1344 
Anavekar, N.S.; Tleyjeh, M.; Anavekar, N.S.; Mirzoyev, Z.; Steckeleberg, J.M.; Haddad, L.; 
Khandaker, M.H.; Wilson, W.R.; Chandrasekaran, K.& Baddour, L.M. (2007). 
Impact of prior antiplatelet therapy on risk of embolism in infectious endocarditis. 
Clinical Infectious Disease, Vol. 44, (2007), pp.1180-1186 
Bjoerkhem-Bergman, L.; Bergman, P.; Andersson, J. & Lindh, J. (2010). Statin treatment and 
mortality in bacterial infections – a systematic review and meta-analysis.  PlosONE, 
Vol5, No5, (2010), e10702 
Blanc, M.; Hsieh, W.Y.; Robertson, K.A.; Watterson, S.; Shui, G.; Lacaze, P.; Khondoker, M.; 
Dickinson, P.; Sing, G.; Rodrigues-Martin, S.; Phelan, P.; Forster, T.; Strobl, B.; 
Mueller, M.; Riemersma, R.; Osborne, T.; Wenk, M.R.; Angulo, A. & Ghazal, P. 
(2011). Host Defense against viral infection involves interferon mediated down-
regulation of sterol biosynthesis. Plos Biology, Vol 9,(2011) e1000598 
Boelaert, J.R.; Van Landuyt, H.W.; De Baere, Y.A; Deruyter, M.M.; Daneels, R.F.; Schurgers, 
M.L.; Matthys, E.G.& Gordts,B.Z. (1950). Staphylococcus aureus infections in 
www.intechopen.com
 
Nontraditional Anti - Infectious Agents in Hemodialysis 
 
403 
haemodialysis patients: pathophysiology and use of nasal mupirocin for 
prevention. Journal of Chemotherapay, Vol.7, Suppl. 3, (1950), pp.43-53 
Breen, J.D. & Karchmer, A.W. (1995). Staphylococcus aureus infections in diabetic patients.  
Infectious Disease Clinic of North America, Vol.9, (1995), pp. 11-24 
Cederlund H., Mardh P.A. (1993). Review: Antibacterial activities of non-antibiotic drugs. 
Journal of Antimicrobial Chemotherapy Vol. 32, (1993) pp.355-365 
Chan, KL., Dumesnil, J.G., Cujec, B., Sanfilippo, A., Jue, J., Turek, M., Robinson, T., & Moher, 
D.(2003). A randomized trial of aspirin on the risk of embolic events in patients 
with infective endocarditis. Journal of the American College of Cardiology, Vol. 42, No 
5, (2003), pp.775-780 
Chan, K.L.; Tam, J.; Dumesnil, J.G.; Cujec, B.; Sanfilippo, A.J.; Jue, J,; Turek, M.; Robinson, 
T.& Williams, K. (2008). Effect of long-term aspirin use on embolic events in 
infective endocarditis. Clinical Infectious Disease, Vol46, (2008), pp. 37-41 
Endo, A.; Kuroda, M. & Tsujita, Y. (1976). ML-236A, ML-236B and ML-236C, new inhibitors 
of cholesterogenesis produced by Penicillium citrinium. Journal of Antibiotics, Vol29. 
(1976) pp. 1346-1348 
Endo, A. (2004) The origin of the statins. Artherosclerosis Supplemen,t Vol.5, (2004), pp. 67-80 
Eisen, D.; Corey,G.,;McBryde,E.; Flowler, V.; Miro, J.; Cabell, C.; Street, A.; Goulart Paiva, 
M.; Ionac, A.; Tan, R.; Tribouilloy, C.; Pachirat, O.; Braun Jones, S.; Chipina, N.; 
Naber, C.; Pan, A.; Ravasio, V.; Gattringer, R.; Chu, V. &Bayer, A. (2009). Reduced 
valve replacement surgery and complication rate in Staphylococcus aureus 
endocarditis patients receiving acetyl-salicylic acid. Journal of Infection, Vol.58, 
No.5,(2009), pp.332-338 
Eisen, D.P. & Bayer, A.S. (2008). Aspirin use in infective endocarditis. Clinical Infectious 
Disease, Vol. 46, (2008), pp. 1481-1482 
Ethier, J.; Bragg-Gesham, J.L.; Piera, L.; Akizawa, T.; Asano, Y.; Mason, N.; Gillespie, B.W.& 
Young, E.W. (2007).  Aspirin prescription and outcomes in hemodialysis patients: 
the dialysis outcomes and practice patterns study (DOPPS). American Journal of 
Kidney Diease, Vol.50, (2007), pp.602-611 
Foley, R.N.; Guo, H.; Snyder, J.J.; Gilbertson, D.T. & Collins, A.J. (2004). Septicemia in the 
United States dialysis population, 1991 to 1999.  Journal of the American Society of 
Nephrology, Vol. 15, (2004), pp. 1038-1045 
Gupta, R.; Plantinga, L.; Fink, N.; Melamed, M., Coresh, J., Fox, C., Levin, N. & Powe,N. 
(2007). Statin use and hospitalization for sepsis in patients with chronic kidney 
disease. Journal of the American Medical Association, Vol. 297, No.13, (2007), pp. 1455-
1464 
Gupta, R.; Plantinga, L.; Fink, N.; Melamed, M.; Coresh, J.; Fox, C.; Levin, N. & Powe,N. 
(2008). Corrections. Journal of the American Medical Association, Vol. 299, No.7, (2008), 
p.765 
Hiremath, S.; Holdren, R.M.; Fergusson, D. & Zimmerman, D.L. (2009). Antiplatelet 
medications in hemodialysis patients: a systematic review of bleeding rates. Clinical 
Journal of the American Society of Nephrology, Vol.4, (2009), pp1347-1355 
Jerwood, S. & Cohen, J. (2008). Unexpected antimicrobial effects of statins. Journal of 
Antimicrobial Chemotherapy, Vol.61, No.2, (2008), pp.362-364 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
404 
Johnson, D.W.; van Eps, C.; Mudge, D.W.; Wiggins, D.W.; Armstrong, K.; Hawley, C.M.; 
Campbell, S.B.; Isbel, N.M.; Nimmo, G.R. & Gibbs, H. (2005). Randomized 
controlled trial of topical exit-site application of honey (Medihoney) for the 
prevention of catheter-associated infections in hemodialysis patients.  Journal of the 
American Society of Nephrology, Vol. 16, (2005), pp. 1456-1462 
Karabay, O.; Arinc, H.; Gundu, Z.; Tamer, A.; Ozhan, H. & Uyan, C. (2006). A new effect of 
acetylsalicylic acid?  Significantly lower prevalence of nasal carriage of 
staphylococcal aureus among patients receiving orally administered acetylsalicylic 
acid.  Infection Control Hospital Epidemiology, Vol 27, (2006),pp. 317-319 
National Kidney foundation: K/DOQI Clinical Practice guidelines for cardiovascular diease 
in dialysis patients.  (2005) American Journal of Kidney Diseases, Vol. 45, Suppl.3, 
(2005), pp. S1-S153 
Kristinasen, J.E. (1992). The antimicrobial activity of non-antibiotics. Report from a congress 
on the antimicrobial effect of drugs other than antibiotics on bacteria, viruses, 
protozoa and other organisms. APMIS Suppl.30, Vol.100, (1992), pp.7-14 
Kristiansen, J.E.; Hendricks, O.; Delvin, T.; Butterworth, T.S.; Aagaard, L.; Christensen, J.B.; 
Flores, V.C. & Keyzer, H. (2007). Reversal of resistance in microorganisms by help 
of non-antibiotics. Journal of Antimicrobial Chemotherapy, Vol.59, (2007), pp 1271-1279 
Kruszewska, H.; Zareba, T. & Tyski, S. (2010). Examination of antimicrobial activity of 
selected non-antibiotic products. Acta Poloniae Pharmaceutica Drug Research, Vol.67 
No.6, (2010), pp.733-736 
Kupferwasser, L.I.; Yeaman, M.R. & Shapiro, S.R. (1999). Acetylsalicylic acid reduces 
vegetation, bacterial density, hematogenous bacterial dissemination and frequency 
of embolic events in experimental staphylococcus aureus endocarditis through 
antiplatelet and antibacterial effects. Circulation, Vol.99, (1999),pp. 2791-2797 
Kupferwasser, L., Yeaman,M.R., Nast, C., Kupferwasser,D.; Xiong,Y., Palma, M., Cheung,A., 
& Bayer, A. (2003). Salicylic acid attenuates virulence in endovascular infections by 
targeting global regulatory pathways in staphylococcus aureus.  Journal of Clinical 
Investigation, Vol.122, No.2, (2003),pp. 222-233 
Laupland, K.B.;Gregson ,D.B.; Zygun, D.A.; Doig, C.J,.; Mortis, G. & Church, D.L. (2004). 
Severe blood stream infections: a population based assessment. Critical Care 
Medicine, Vol. 32, (2004), pp. 992-997 
Liao, J.K. & Laufs, U. (2005) Pleiotropic effects of statins. Annual Review of Pharmacology and 
Toxicology, Vol.45, (2005), pp. 89-118 
Little, M.A.; O’Riordan, A.; Lucey, B. et al. (2001). A prospective study of complications 
associated with cuffed tunneled haemodialysis catheters. Nephrology Dialysis 
Transplantation, Vol 16,(2001), pp. 2194-2200 
Liu, G.Y. & Nizrt, V. (2009). Colour me bad: microbial pigments as virulence factors. Trends 
in Microbiology, Vol. 17, (2009), pp. 406-413 
Namias, N. (2003) Honey in the management of infections. Surgical Infection, Vol.4, (2003), 
pp. 219-226 
Nicolau, D.P.; Freeman, C.D.; Nightingale, C.H.; Quintiliani, R.; Coe, C.J.; Maderazo, E.G. & 
Cooper, B.W. (1993). Reduction of bacterial titers by low-dose aspirin in 
experimental aortic valve endocarditis. Infection and Immunity, Vol.61, (1993), pp. 
1593-1595 
www.intechopen.com
 
Nontraditional Anti - Infectious Agents in Hemodialysis 
 
405 
Nicolau, D.P.; Marangos, M.N.; Nightingale, C.H. & Quintiliani, R. (1995). Influence of 
Aspirin on development and treatment of experimental Staphylococcus aureus 
endocarditis.  Antimicrobial Agents and Chemotherapy, Vol.39, (1995), pp. 1748-1751 
Olyaei, A.; Greer, E.; Delos Santos, R. & Rueda, J. (2011) The efficacy and safety of 3-
hydroxy-3-methylglutaryl-CoA esterase inhibitors in chronic kidney disease, 
dialysis and transplant patients. Clinical Journal of the American Society of Nephrology, 
Vol6, (2011), pp. 664-678 
Paterson, J.R. & Lawrence, J.R. (2001), Salicylic acid: a link between aspirin, diet and the 
prevention of colorectal cancer. Quarterly Journal of Medicine, Vol. 94, (2001), pp. 
445-448 
Peacock, S.J.; Eddleston, M.; Emptage, A.; King, A. & Crook, D.W. (1998) Positive 
intravenous line tip cultures as predictors of bacteremia. Journal of Hospital Infection, 
Vol. 40, (1998), pp. 35-38 
Percival, S.L.; Kite, P.; Eastwood, K.; Murga, R.; Carr, J.; Arduino, M.J. & Donlan, R.M. 
(2005). Tertrasodium EDTA as a novel central venous catheter lock solution against 
biofilm. Infection Control Hospital Epidemiology Vol. 26 (2005), pp.511-514 
Pujadas, R.E.; Escriva, F.; Jane, J.; Argimon, J.; Fava, P. & Calera, M.C. (1988). Effect of 
various doses of aspirin on the development of aseptic thrombotic aortic 
endocarditis experimentally induced in the rabbit. Revista Espanola de Cardiologia, 
Vol. 41,(1988), pp 31-34 
Rayner, H.C.; Besarab, A.; Brown, W.; Disney, A.; Saito, A. & Pisoni, R.L. (2004). Vascular 
access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): 
performance against kidney disease outcomes quality initiative (K/DOQI) clinical 
practice guidelines. American Journal of Kidney Disease, Vol. 44, Suppl.2, (2004), pp. 
S22-S26 
Ruder, E.H.; Layemo, A.O.; Graubard, B.I.; Hollenbeck, A.R.; Schatzkin, A & Cross, A.J. 
(2011). Non steroidal anti-inflammatory drugs and colorectal cancer risk in a large 
prospective cohort.  American Journal of Gastroenterology, (2011), (e-published before 
print) 
Sedlacek, M.; Gemery, J.; Cheung, A.; Bayer, A. & Remillard, B. (2007). Aspirin Treatment is 
associated with a significantly decreased risk of Staphylococcus aureus bacteremia 
in Hemodialysis patients with tunneled catheters. American Journal of Kidney 
Diseases, Vol. 49, No.3, (2007), pp. 401-408 
Sedlacek, M.; Kaneko, T.; Schoolwerth, A. & Remillard, B.(2008) Septicemia due to vascular 
access is a rare cause of death in dialysis patients treated with aspirin. Journal of the 
American Society of Nephrology, Vol.19, (2007), abstract F-PO1586 
Schunemann, S.; Werner, G.S.; Schulz, R.; Bitsch, A.; Prange, H.W. & Kreutzer, H. (1997). 
Embolische Komplikationen bei bacterieller Endokarditis. Zeitschrift fuer Kardiologie, 
Vol.86,(1997), pp1017-1025 
Shanks, R.M.Q.; Donegan, N.P.; Graber, M.L.; Buckingham, S.E.; Zegans, M.; Cheung, A.L. 
& O’Toole, G.A. (2005). Heparin stimulates staphylococcus aureus biofilm 
formation. Infection and Immunity, Vol. 73, No 8, (2005), pp. 4596-4606 
Shanks, R.M.Q.; Sargent, J.L.; Martinez, R.M.; Graber, M.L. & O’Toole, G.A. (2006). Catheter 
lock solutions influence staphylococcal biofilm formation on abiotic surfaces. 
Nephrology Dialysis Transplantation, Vol. 21, (2006), pp. 2247-2255 
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
406 
Taha, T.H.; Durrant, S.S.; Mazeika, P.K.; Nihoyannopoulos,P. & Oakley, C.M. (1992). Aspirin 
to prevent growth of vegetations and cerebral emboli in infective endocarditis. 
Journal of Internal Medicine, Vol. 231, (1992), pp. 543-546 
Vandecasteele, S.J.; Boelaert , J.R. & De Vriese, A.S. (2009). Staphylococcus aureus infections 
in hemodialysis: what a nephrologist should know. Clinical Journal of the American 
Society of Nephrology, Vol.4, (2009), Pp. 1388-1400 
VanderBergh, M.F.; Yzerman, E.P.; van Belkum, A.; Boelens, H.A;, Sijmons, M. & Verbrugh, 
H.A (1999). Follow up of Staphylococcus aureus nasal carriage after eight years: 
redefining the persistent carrier state. Journal of  Clinical Microbiology, Vol 37, (1999), 
pp .3133-3140 
Von Eiff, C.; Becker, K.; Machka, K.; Stammer, H. & Peters, G. (2001). Nasal carriage as a 
source of staphylococcus aureus bacteremia. New England Journal of Medicine, Vol. 
344, (2001), pp11-16 
Williams J.D. (1995). The Garrod lecture: Selective toxicity and concordant 
pharmacodynamics of antibiotics and other drugs. Journal of Antimicrobial 
Chemotherapy, Vol35, (1995), pp.721-737 
Wanner, C.; Kanne, V. & Marz, W. (2005). Atorvastatin in patients with type 2 diabetes 
mellitus undergoing hemodialysis. New England Journal of Medicine, Vol. 353, (2005), 
pp 238-248 
www.intechopen.com
Progress in Hemodialysis - From Emergent Biotechnology to
Clinical Practice
Edited by Prof. Angelo Carpi
ISBN 978-953-307-377-4
Hard cover, 444 pages
Publisher InTech
Published online 07, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Hemodialysis (HD) represents the first successful long-term substitutive therapy with an artificial organ for
severe failure of a vital organ. Because HD was started many decades ago, a book on HD may not appear to
be up-to-date. Indeed, HD covers many basic and clinical aspects and this book reflects the rapid expansion of
new and controversial aspects either in the biotechnological or in the clinical field. This book revises new
technologies and therapeutic options to improve dialysis treatment of uremic patients. This book consists of
three parts: modeling, methods and technique, prognosis and complications.
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